Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Emerging Insights on Adverse Events During ART and Implications for Treatment: Key Data From Fall 2021
  • CME
  • CE

Gregory Huhn, MD, MPHTM
Released: December 22, 2021
Back Next

References

  1. Wood BR, Huhn GD. Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter? Open Forum Infect Dis. 2021;8(12):ofab542.
  2. Patel Y, Doshi A, Levesque A, et al. Improvement in diet attenuates antiretroviral therapy (ART) associated weight gain in persons with human immunodeficiency virus (PWH). Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 835.
  3. Shah S, Pilkington V, Hill A. Use of tenofovir disoproxil fumarate shows weight loss vs placebo: a meta-analysis of 7 clinical trials in 19,359 HIV-negative individuals. Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 882.
  4. FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. hiv.gov/blog/fda-approves-first-drug-for-reducing-the-risk-of-sexually-acquired-hiv-infection. Accessed December 12, 2021.
  5. Phupitakphol T, Hawkins K, McEwan D, et al. Massive weight gain in people with HIV (PWH) starting initial antiretroviral therapy (ART): risk factors and predictive ability of early weight gain. Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 72.
  6. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:153-160.
  7. Phillips AN, Katlama C, Barton S, et al. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:239-244.
  8. Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020;21:71-83.
  9. Bannister W, Mast TC, Peters L, et al. Change in body mass index (BMI) and association with clinical outcomes after initiation of contemporary HIV antiretroviral (ARV) regimens in EuroSIDA. Presented at: 18th European AIDS Conference; October 27-30, 2021. Abstract PE5/12.
  10. Rebeiro PF, Jenkins CA, Bian A, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. Clin Infect Dis. 2021;73:e2234-e2242.
  11. Ronit A, Haissman J, Kirkegaard-Klitbo DM, et al. Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. BMC Infect Dis. 2016;16:713.
  12. Høgh J, Gelpi M, Skovsgaard MH, et al. Insulin resistance in PWH is associated with abdominal obesity and prior exposure to thymidine analogues and/or didanosine. Presented at: 18th European AIDS Conference; October 27-30, 2021. Abstract PE3/8.
  13. Daar E, Orkin C, Sax P, et al. Incidence of metabolic complications among treatment-naive adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks. Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 69.
  14. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020;71:1920-1929.
  15. Osiyemi O, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based Regimen (TBR) in maintaining virologic suppression through 144 weeks (TANGO Study). Presented at: IDWeek 2021; September 29 - October 3, 2021 Virtual. Abstract 900.
  16. Hutfless S, Gudzune KA, Maruthur N, et al. Strategies to prevent weight gain in adults: a systematic review. Am J Prev Med. 2013;45:e41-51.
  17. van Wyk J, Ait-Khaled M, Santos J, et al. Metabolic health outcomes at week 144 in the TANGO study comparing a switch to DTG/3TC versus maintenance of TAF-based regimens. Presented at: 11th IAS Conference on HIV Science; July 18-21, 2021. Abstract PEB164.
  18. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-2615.
  19. Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75:226-231.
  20. Milinkovic A, Berger F, Arenas-Pinto A, et al. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back. AIDS. 2019;33:2387-2391.
  21. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211-e220.
  22. Molina JM, Squires K, Sax P, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD noninferiority trial. Presented at: 2018 International AIDS Conference; July 23-27, 2018. Abstract LBPEB017.
  23. Cahn P, Molina J-M, Lombaard Johan, et al. The efficacy and safety of maintenance with doravirine plus two NRTIs after initial suppression in adults with HIV-1 in the DRIVE-FORWARD clinical trial: results from the study extension through 192 weeks. Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 626.
  24. Bischoff J, van Bremen K, Boesecke C, et al. Hepatic steatosis associated with integrase strand inhibitors - does the substance matter? Presented at: 18th European AIDS Conference; October 27-30, 2021. Abstract PE3/80.
  25. Hill A, McCann KM, Pilkington V, et al. Risks of metabolic syndrome, diabetes, and cardiovascular disease in ADVANCE trial. Presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2021. Abstract 81.
  26. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803-815.
  27. Qavi A, Venter F, Sokhela S, et al. Week 192 bone and renal markers from the ADVANCE trial. Presented at: 18th European AIDS Conference; October 27-30, 2021. Abstract PE2/62.
  28. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379:979-981.
  29. FDA. FDA Drug Safety Communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq). September 2018. fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluate-potential-risk-neural-tube-birth-defects-hiv-medicine. Accessed December 12, 2021.
  30. Vannappagari V, Albano J, Ragone L, et al. Maternal dolutegravir (DTG) use during pregnancy and birth outcomes: the Antiretroviral Pregnancy Registry (APR). Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 74.
  31. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1 January 1989 through 31 January 2021. Wilmington, NC: Registry Coordinating Center; 2021. APRegistry.com. Accessed December 12, 2021.
  32. DHHS. Panel on treatment of pregnant women with HIV infection and prevention of perinatal transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. npin.cdc.gov/publication/recommendations-use-antiretroviral-drugs-pregnant-hiv-1-infected-women-maternal-health. Accessed December 12, 2021.
  33. Zash R, Holmes L, DIseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana. Presented at: 2020 International AIDS Conference; July 6-10, 2020. Abstract OAXLB0102.
  34. Patel P, Ford SL. Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. Presented at: IDWeek 2021; September 29 - October 3, 2021. Abstract 885.
  35. Patel P. Special populations including end organ failure: focus on long-acting cabotegravir and rilpivirine. Presented at: International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs; September 20-22, 2021.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings